

***Remarks***

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendments, claims 1-8 are pending in the application, with claims 1, 4, 5 and 7 being the independent claims. New claim 8 is sought to be added.

Claims 4, 5 and 7 were amended to place them in independent form. Claim 8 was added to further specify the uses for the pharmaceutical composition. Support for new claim 8 can be found at page 11, line 11 through page 12, line 19. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Based on the above amendments and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

***Objection to the Claims***

Claims 4, 5 and 7 were objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Claims 4, 5 and 7 have been amended accordingly. It is respectfully requested that the objection to the claims be withdrawn.

***Rejections under 35 U.S.C. § 112***

Claims 5-7 were rejected under 35 U.S.C. § 112, first paragraph, because the specification is allegedly not enabling for preventing obesity, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy. The phrase "or preventing" has been deleted from claims 5-7.

Claims 5 and 7 were rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite. The Examiner stated that the exact meaning of the term "related disorders" is unclear. The phrase "related disorders" has been deleted from claims 5 and 7.

It is respectfully requested that the rejections under 35 U.S.C. § 112 be withdrawn.

***Allowable Claims***

The Examiner has indicated that claims 1-3 are allowed.

***Other Matters***

Applicants note that the 35 U.S.C. § 371 date is incorrect. The Notice of Acceptance and the Official Filing Receipt list a 35 U.S.C. § 371 date of May 2, 2007. However, the correct 35 U.S.C. § 371 date is March 2, 2007. Applicants note that the declaration was filed March 2, 2007 and not May 2, 2007 as listed on the Notice of Acceptance. Thus, the date of completion of all 35 U.S.C. § 371 requirements is March 2, 2007.

Applicants filed a Request to Correct 35 U.S.C. § 371 Date and a Request for Corrected Official Filing Receipt on June 7, 2007. To date, Applicants have not received a notice indicating that the requests have been acknowledged by the USPTO.

***Conclusion***

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Judith U. Kim Reg. No. 40,679*  
*for Danielle L. Letting*  
Agent for Applicants  
Registration No. 56,971

Date: January 4, 2008

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

762965\_1.DOC